Analysis Of Factors Influencing Bleeding In Patients With Non-valvular Atrial Fibrillation Treated With Rivaroxaban

Objective: To investigate the possible appropriate application dose of rivaroxaban in patients with non-valvular atrial fibrillation and to study the effects of different factors on patients with non-valvular atrial fibrillation.METHODS: In this study,106 patients with non-valvular atrial fibrillation admitted to the Fifth Affiliated Hospital of Xinjiang Medical University from June 2021 to June 2022,including 54 males and 52 females;aged 28-92 years,mean 76 years,were selected and divided into a bleeding group and a non-bleeding group according to whether the patients had bleeding on oral rivaroxaban.In the bleeding group,there were 35 patients,18 males and 17 femininity,evage 50-92 years,even 80 years,with a body mass index(BMI)of 16.14-30.11 kg/m2,average 23.94 kg/m2.71 patients in the non-bleeding group,36 males and 35 females,aged 28-90 years,average72 years,with a BMI of 13.43 ～Thirty-five patients had clinically significant bleeding,with an overall incidence of 33.0%,of whom 32(91.4%)had clinically significant non-major bleeding.There were three clinically relevant major bleeding events(8.6%)and a total of 24 patients with thromboembolic events,with an overall incidence of 22.64%,of whom 15(62.5%)had a new cerebral infarction.General information,coagulation indexes,bleeding and thromboembolism,and factor Xa activity were retrospectively analysed in both groups.Results:(1)CHA2DS2-VASC scores and creatinine clearance were significantly higher in patients with non-valvular atrial fibrillation who experienced clinically relevant bleeding events during anticoagulation therapy with rivaroxaban than in patients who did not experience clinically relevant bleeding events;(2)the dose of rivaroxaban was an independent risk factor for clinically significant bleeding during anticoagulation with rivaroxaban in patients with non-valvular atrial fibrillation;(3)Xa factor activity was linearly correlated with the dose of rivaroxaban;(4)Higher incidence of stroke in the 10 mg/day group,suggesting that a 15 mg/day dose of rivaroxaban may be more appropriate.